I am a
Home I AM A Search Login

Papers of the Week

2022 Sep 23

Int J Hematol

Recurrent pain attacks during romiplostim treatment in a patient with ITP carrying a heterozygous MEFV mutation.


Kinoshita S, Komatsu H, Fujinami H, Yoshida T, Suzuki T, Narita T, Ito A, Ri M, Kusumoto S, Iida S
Int J Hematol. 2022 Sep 23.
PMID: 36149532.


We report a case of recurrent pain attacks during romiplostim treatment in a woman with immune thrombocytopenia carrying a heterozygous MEFV mutation. Five months after starting treatment with romiplostim for immune thrombocytopenia, she was diagnosed with idiopathic pericarditis. She was switched to eltrombopag, but thrombocytopenia did not improve. Romiplostim was restarted 7 months later, although she then developed recurrent right hypochondrial pain. The pain typically occurred three days after the romiplostim injection and resolved two days later. She had never experienced such recurrent pain before starting romiplostim or after discontinuing it. Genetic analysis showed that she carried a heterozygous R202Q alteration in exon 2 of the MEFV gene. MEFV mutation is known to cause familial Mediterranean fever, which is characterized by symptoms such as recurrent fever, abdominal and chest pain, arthritis, and pericarditis. This case suggests that romiplostim has the potential to trigger recurrent pain/inflammation attacks in individuals with systemic inflammatory abnormalities.